|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo P, Huang ZL, Yu P and Li K: Trends in
cancer mortality in China: An update. Ann Oncol. 23:2755–2762.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grädler U, Schwarz D, Dresing V, Musil D,
Bomke J, Frech M, Greiner H, Jäkel S, Rysiok T, Müller-Pompalla D
and Wegener A: Structural and biophysical characterization of the
Syk activation switch. J Mol Biol. 425:309–333. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coopman PJ and Mueller SC: The Syk
tyrosine kinase: A new negative regulator in tumor growth and
progression. Cancer Lett. 241:159–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coopman PJ, Do MT, Barth M, Bowden ET,
Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH
and Mueller SC: The Syk tyrosine kinase suppresses malignant growth
of human breast cancer cells. Nature. 406:742–747. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang L, Devarajan E, He J, Reddy SP and
Dai JL: Transcription repressor activity of spleen tyrosine kinase
mediates breast tumor suppression. Cancer Res. 65:10289–10297.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Shrikhande U, Alicie BM, Zhou Q
and Geahlen RL: Role of the protein tyrosine kinase Syk in
regulating cell-cell adhesion and motility in breast cancer cells.
Mol Cancer Res. 7:634–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ogane S, Onda T, Takano N, Yajima T,
Uchiyama T and Shibahara T: Spleen tyrosine kinase as a novel
candidate tumor suppressor gene for human oral squamous cell
carcinoma. Int J Cancer. 124:2651–2657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen
G, Yang L, Li B, Huang P, Chen D, et al: CHK1 targets spleen
tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J
Clin Invest. 122:2165–2175. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakashima H, Natsugoe S, Ishigami S,
Okumura H, Matsumoto M, Hokita S and Aikou T: Clinical significance
of nuclear expression of spleen tyrosine kinase (Syk) in gastric
cancer. Cancer Lett. 236:89–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng C, Sun Q, Hao Y, Cong B, Zhao Y and
Zhao X: Syk is low-expressed in non-small-cell lung cancer and
inversely correlates with patient's survival. Acta Bioch Biophys
Sin (Shanghai). 45:149–151. 2013. View Article : Google Scholar
|
|
12
|
Yang Z, Huo L, Chen H, Ni B, Xiang J, Kang
L, Wang L, Peng J, Yuan Y and Wang J: Hypermethylation and
prognostic implication of Syk gene in human colorectal cancer. Med
Oncol. 30:2013. View Article : Google Scholar
|
|
13
|
Layton T, Stalens C, Gunderson F, Goodison
S and Sillett S: Syk tyrosine kinase acts as a pancreatic
adenocarcinoma tumor suppressor by regulating cellular growth and
invasion. Am J Pathol. 175:2625–2636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan YF, Wang JP, Li JP, Wang L, Li M,
Yang Z, Zhang C and Dai JL: Frequent epigenetic inactivation of
spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin
Cancer Res. 12:6687–6695. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peng CL, Zhang Y, Sun QF, Zhao YP, Hao YT,
Zhao XG and Cong B: Inhibitory effects of Syk transfection on lung
cancer cell invasion. Asian Pac J Cancer Prev. 14:3001–3003. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luangdilok S, Box C, Patterson L, Court W,
Harrington K, Pitkin L, Rhŷs-Evans P, O-charoenrat P and Eccles S:
Syk tyrosine kinase is linked to cell motility and progression in
squamous cell carcinomas of the head and neck. Cancer Res.
67:7907–7916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du ZM, Kou CW, Wang HY, Huang MY, Liao DZ,
Hu CF, Chen J, Yan LX, Hu LF, Ernberg I, et al: Clinical
significance of elevated spleen tyrosine kinase expression in
nasopharyngeal carcinoma. Head Neck. 34:1456–1464. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Duke L, Zhang PS, Arlinghaus RB,
Symmans WF, Sahin A, Mendez R and Dai JL: Alternative splicing
disrupts a nuclear localization signal in spleen tyrosine kinase
that is required for invasion suppression in breast cancer. Cancer
Res. 63:4724–4730. 2003.PubMed/NCBI
|
|
19
|
Hong J, Yuan YF, Wang JP, Liao Y, Zou R,
Zhu C, Li B, Liang Y, Huang P, Wang Z, et al: Expression of variant
isoforms of the tyrosine kinase SYK determines the prognosis of
hepatocellular carcinoma. Cancer Res. 74:1845–1856. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Prinos P, Garneau D, Lucier JF, Gendron D,
Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, et al:
Alternative splicing of SYK regulates mitosis and cell survival.
Nat Struct Mol Biol. 18:673–679. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan Y, Mendez R, Sahin A and Dai JL:
Hypermethylation leads to silencing of the SYK gene in human breast
cancer. Cancer Res. 61:5558–5561. 2001.PubMed/NCBI
|
|
22
|
Yan C, Liu C, Jin Q, Li Z, Tao B and Cai
Z: The promoter methylation of the Syk gene in nasopharyngeal
carcinoma cell lines. Oncol Lett. 4:505–508. 2012.PubMed/NCBI
|
|
23
|
Shin SH, Lee KH, Kim BH, Lee S, Lee HS,
Jang JJ and Kang GH: Downregulation of spleen tyrosine kinase in
hepatocellular carcinoma by promoter CpG island hypermethylation
and its potential role in carcinogenesis. Lab Invest. 94:1396–1405.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Davies JM and Goldberg RM: Treatment of
metastatic colorectal cancer. Semin Oncol. 38:552–560. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen L, Yu M, Xu X, Gao L, Ni J, Luo Z and
Wu S: Knockdown of β3GnT8 reverses 5-fluorouracil resistance in
human colorectal cancer cells via inhibition the biosynthesis of
polylactosamine-type N-glycans. Int J Oncol. 45:2560–2568.
2014.PubMed/NCBI
|
|
27
|
Ladomery M: Aberrant alternative splicing
is another hallmark of cancer. Int J Cell Biol. 2013:4637862013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hatakeyama K, Wakabayashi-Nakao K, Ohshima
K, Sakura N, Yamaguchi K and Mochizuki T: Novel protein isoforms of
carcinoembryonic antigen are secreted from pancreatic, gastric and
colorectal cancer cells. BMC Res Notes. 6:3812013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kahkhaie KR, Moaven O, Abbaszadegan MR,
Montazer M and Gholamin M: Specific MUC1 splice variants are
correlated with tumor progression in esophageal cancer. World J
Surg. 38:2052–2057. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jacob AG, O'Brien D, Singh RK, Comiskey DF
Jr, Littleton RM, Mohammad F, Gladman JT, Widmann MC, Jeyaraj SC,
Bolinger C, et al: Stress-induced isoforms of MDM2 and MDM4
correlate with high-grade disease and an altered splicing network
in pediatric rhabdomyosarcoma. Neoplasia. 15:1049–1063. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Venables JP, Klinck R, Bramard A, Inkel L,
Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U,
Durand M, et al: Identification of alternative splicing markers for
breast cancer. Cancer Res. 68:9525–9531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miura K, Fujibuchi W and Unno M: Splice
isoforms as therapeutic targets for colorectal cancer.
Carcinogenesis. 33:2311–2319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Geahlen RL: Getting Syk: Spleen tyrosine
kinase as a therapeutic target. Trends Pharmacol Sci. 35:414–422.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Puissant A, Fenouille N, Alexe G, Pikman
Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, et
al: SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Cancer Cell. 25:226–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shakeel S, Mahjabeen I, Kayani MA and
Faryal R: Association of SYK genetic variations with breast cancer
pathogenesis. Asian Pac J Cancer Prev. 14:3309–3314. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoellenriegel J, Coffey GP, Sinha U,
Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S,
Keating MJ and Burger JA: Selective, novel spleen tyrosine kinase
(Syk) inhibitors suppress chronic lymphocytic leukemia B-cell
activation and migration. Leukemia. 26:1576–1583. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bailet O, Fenouille N, Abbe P, Robert G,
Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne JP,
Ballotti R, et al: Spleen tyrosine kinase functions as a tumor
suppressor in melanoma cells by inducing senescence-like growth
arrest. Cancer Res. 69:2748–2756. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sung YM, Xu X, Sun J, Mueller D, Sentissi
K, Johnson P, Urbach E, Seillier-Moiseiwitsch F, Johnson MD and
Mueller SC: Tumor suppressor function of Syk in human MCF10A in
vitro and normal mouse mammary epithelium in vivo. PLoS One.
4:e74452009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Larive RM, Urbach S, Poncet J, Jouin P,
Mascré G, Sahuquet A, Mangeat PH, Coopman PJ and Bettache N:
Phosphoproteomic analysis of Syk kinase signaling in human cancer
cells reveals its role in cell-cell adhesion. Oncogene.
28:2337–2347. 2009. View Article : Google Scholar : PubMed/NCBI
|
